SmallCapReview - Stocks to Watch - TPAC, MAT, ALXN

Trans-Pacific Aerospace Company, Inc. (OTCBB: TPAC) $0.31. Announced Thursday after market close that it has successfully achieved all fundamental milestones that will enable the company to begin the qualification process in June 2010.

"I am extremely pleased with the outcome of our trip to China," said Bill McKay, Trans-Pacific Aerospace CEO. "We have strong partners, tremendous local government support, and an excellent supply chain, as well as a facility in an ideal location close to the port, our suppliers and machine tool manufacturers."

Godfrey (China) Ltd., Trans-Pacific's partner (of which it owns 25%), facilitated formation of a Wholly Foreign Owned Enterprise (WFOE) which enables the company to do business domestically and export its goods globally. McKay commented, "Our company is one of just a handful of high-tech companies in Zhongshan, China, and the city's first aerospace company. Post-qualification, Trans-Pacific Aerospace would be the only company in China qualified to make SAE-AS81820, SAE-AS81934 and SAE-AS81935 spherical bearings, bushings and rod end bearings that are used throughout commercial aircraft produced by manufacturers like Airbus and Boeing ."

Trans-Pacific Aerospace Company also announced today that it has successfully passed internal testing for liner bond integrity and peel strength, as outlined in SAE-AS81820. This SAE standard is the standard to which the Company intends to qualify its self-lubricating bearings to be produced in China.

Bill McKay commented, "We are very happy with the results of the prototype test. This success puts us on track for qualification and is a critical and necessary step in the qualification process. The success speaks to the quality of our tooling, bearing design and the bonding process being employed. It shows the skill of our qualification team in producing high quality bearings. In addition to the successful testing, all tooling for the qualification has been manufactured and approved by Trans-Pacific Aerospace Company. Furthermore, component designs have been turned into prototype parts and have been successfully manufactured. Our prototype parts look great, so full production of all SAE qualification test components has commenced and we expect them to be completed in time to meet our schedule for qualification production, testing and acceptance."

Trans-Pacific Aerospace Company plans to use its proprietary aerospace bearing technologies to manufacture and sell component parts for both new commercial aircraft and spares for the existing commercial fleet, initially through a joint venture in China. The component parts are referred to as self-lubricating spherical bearings, and they help with several flight critical tasks including aircraft flight controls and landing gears.

What They Do: Trans-Pacific Aerospace (TPAC) deals in proprietary aerospace bearing technologies and is a manufacturer of spare parts for both new and existing commercial air fleets.

Mattel, Inc. (Nasdaq: MAT) $23.75. Today announced 2010 first quarter financial results. For the quarter, the company reported net income of $24.8 million, or $0.07 per share, compared to last year’s first quarter net loss of $51.0 million, or $0.14 per share.

For the quarter, net sales were $880.1 million, up 12 percent compared to $785.6 million last year, including favorable changes in currency exchange rates of 3 percentage points. On a regional basis, first quarter gross sales increased 12 percent in the U.S. and increased 12 percent in international markets, including favorable changes in currency exchange rates of 7 percentage points. Operating income for the quarter was $45.2 million, compared to prior year’s operating loss for the quarter of $55.2 million.

Alexion Pharmaceuticals (Nasdaq: ALXN) $54.94. Today announced that Japan ’s Ministry of Health, Labour and Welfare (MHLW) has approved the Company’s New Drug Application (NDA) for the use of Soliris (eculizumab) as a treatment for patients in Japan with paroxysmal nocturnal hemoglobinuria (PNH). PNH is an ultra-rare, debilitating and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis. Soliris, a first-in-class terminal complement inhibitor, is the first therapy approved in Japan for the treatment of patients with PNH. Soliris received orphan drug designation from the MHLW in 2009 and was approved under the Ministry’s priority review process.

“The speedy approval of the Soliris NDA in Japan underscores the severity of PNH in Japanese patients and the significant clinical impact that this treatment provides to patients living with PNH,” said Leonard Bell, M.D., Chief Executive Officer of Alexion. “This regulatory approval marks another important step in our global commitment to the objective of providing access to Soliris to all patients who can benefit from it. We now look forward to working closely with the healthcare authorities in Japan to make Soliris available to patients as rapidly as possible.”

About SmallCapReview

Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.

The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SmallCapReview may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our website or within our reports  In order to be in full compliance with the Securities Act of 1933, Section 17(b), SCR will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SmallCapReview website. SmallCapReview has been compensated four thousand dollars dollars by a third party Green Horseshoe for its services with regards to Trans-Pacific Aerospace.